Mi-RNA and COVID-19

Circulating Mi-RNA Associated With Disease Severity and Outcome in COVID-19 Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06881160

Enrollment

Registered

2025-03-18

Start date

2020-03-01

Completion date

2027-12-01

Last updated

2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease, characterized by respiratory failure, shock and multi-organ dysfunction requiring admission in the intensive care unit (ICU). The aim of the present study is to analyze miRNAs associated with SARS-CoV-2 infection, disease severity and mortality.

Interventions

DIAGNOSTIC_TESTmi-RNA analysis

To identify biomarkers that could predict the risk of a worsened COVID-19 disease progression.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years * diagnosis of SARS-CoV-2 infection confirmed by molecular testing on nasopharyngeal swabs

Exclusion criteria

* pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Severity of Covid-19	Through study completion, an average of 1 year	Severity of the disease

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026